Engineering Smarter, Targeted Immunotherapies for Cancer and Autoimmune
The Immunotherapy Stream at PEGS Boston delves into cutting-edge engineering strategies revolutionizing immunotherapies for cancer and autoimmune diseases via antibody, protein, and cell-based approaches.
Part One delves into recent advancements in immunotherapies for solid tumors and autoimmune diseases, highlighting checkpoint inhibitors, immune cell engagers, TCR therapies, and exploring innovative targets and combination strategies. Part Two examines the development of fitter, more effective, and safer cellular immunotherapies tailored for cancer and autoimmune diseases, emphasizing engineering improvements that enhance therapeutic efficacy, endurance, and clinical outcomes. Part Three investigates emerging immune reprogramming technologies, featuring in vivo engineering, targeted delivery mechanisms to immune cells, and AI-driven methods for discovering new therapeutic targets. This section also covers next-generation T cell engagers, viral and microbial-based immunotherapies, offering a forward-looking perspective on the evolving landscape of immunotherapy across various modalities and clinical indications. Together, these sections provide a comprehensive overview of the current state and exciting future of immunotherapy development.
Conferences Include:
May 12-13
Advances in Immunotherapy
May 13-14
Engineering Cell Therapies
May 15-16
Next-Generation Immunotherapies